BioTuesdays: Tonix developing treatment overlap for fibromyalgia and PT
October 8, 2013 by leonardzehr · Leave a Comment
After initiating enrollment of a Phase 2b/3 clinical trial of TNX-102 SL in fibromyalgia (FM) patients earlier this month, Tonix Pharmaceuticals Holding (NASDAQ:TNXP) is now setting its sights on a Phase 2a trial of its drug candidate as a treatment for post-traumatic stress disorder (PTSD).
“About 50% of FM and PTSD patients meet the criteria for the other disorder,” CFO Dr. Leland Gershell says in an interview with BioTuesdays. “In FM, patients hurt all over and can’t get restorative sleep; in PTSD, patients experience disturbed sleep and widespread pain.”
Dr. Gershell explains that Tonix’s treatment concept with TNX-102 SL, a sublingual tablet that dissolves under the tongue, is a nightly bedtime therapy designed to improve pain and other daytime symptoms by improving sleep quality.....
...see BioTuesdays for the rest of this week's feature article on TNXP